¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚÎÒÃÇ ¤™
-
¿Æ¼¼´´Ð ¤™
-
²úÆ·ÓëÒµÎñ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°Òµ·¢Õ¹ ¤™
¼ò
¤™
- Mocertatug rezetecan×÷Ϊµ¥µÏÍþ¹ú¼ÊÖÎÁƼ°Óë±´·¥Öéµ¥¿¹ÁªºÏÓõÏÍþ¹ú¼Ê£¬ÔÚÖضȾÖεIJ¬Ãô¸Ð¸´·¢Âѳ²°©£¨PSOC£©»¼ÕßÖÐÏÔʾ³ö¿¹Ö×Áö»îÐÔ£¬°²È«ÐÔ¿É¿Ø¡£
Mocertatug rezetecanÊÇÒ»¿î°ÐÏòB7-H4µÄ¿¹ÌåµÏÍþ¹ú¼ÊÎïżÁªÎADC£©£¬Ä¿Ç°Õý´¦ÓÚÁÙ´²¿ª·¢½×¶Î£¬ÓÃÓÚÖÎÁƸ¾¿ÆÖ×Áö£¨°üÀ¨×Ó¹¬ÄÚĤ°©ºÍÂѳ²°©£©¡£ÔÚESGO 2026ÉϹ«²¼µÄÊý¾ÝÆÀ¹ÀÁËmocertatug rezetecan×÷Ϊµ¥µÏÍþ¹ú¼ÊÒÔ¼°Óë±´·¥Öéµ¥¿¹ÁªºÏÓõÏÍþ¹ú¼ÊÔÚ²¬Ãô¸Ð¸´·¢Âѳ²°©£¨PSOC£©»¼ÕßÖеÄÖÎÁÆЧ¹û¡£Á½ÏîÑо¿¾ùÏÔʾ£¬mocertatug rezetecan¾ßÓп¹Ö×Áö»îÐÔ£¬ÇÒ°²È«ÐÔÌØÕ÷Óë´ËÇ°Ñо¿Ò»Ö¡£
ÕâЩÊý¾Ý·Ö±ðÀ´×ÔÁ½Ï·Å±êÇ©Ñо¿£º
HS-20089-201Ñо¿£ºÒ»ÏîÖ¼ÔÚÆÀ¹Àmocertatug rezetecanÔÚÖйú¸´·¢»òתÒÆÐÔÂѳ²°©ºÍ×Ó¹¬ÄÚĤ°©»¼ÕßÖеÄÁÆЧ¡¢°²È«ÐÔ¡¢µÏÍþ¹ú¼Ê´ú¶¯Á¦Ñ§ºÍÃâÒßÔÐÔµÄIIÆÚÑо¿£¬ÆäÖв¬Ãô¸ÐÂѸ´·¢³²°©¶ÓÁУ¨PSOC£©µÄ½á¹ûÔÚ±¾´Î´ó»áÒÔ±Ú±¨ÐÎʽչʾ¡£
HS-20089-103Ñо¿£ºÒ»ÏîÖ¼ÔÚÆÀ¹Àmocertatug rezetecanÁªºÏÖÎÁÆÔÚÍíÆÚʵÌåÁö»¼ÕßÖеÄIÆÚÑо¿£»ÆäÖÐmocertatug rezetecanÁªºÏ±´·¥Öéµ¥¿¹ÖÎÁƲ¬Ãô¸Ð¸´·¢Âѳ²°©£¨PSOC£©¶ÓÁÐÊý¾ÝÔÚ±¾´Î´ó»áÒÔ×îÐÂÍ»ÆÆÕªÒª£¨LBA£©µÄÃÔÄã¿ÚÍ·±¨¸æÐÎʽ½øÐÐչʾ¡£
ÕâЩÑо¿½á¹ûÓÐÖúÓÚ¸üÉîÈëµØÀí½âÍØÆËÒ칹ø1ÒÖÖƼÁÀàADCÔÚ²¬Ãô¸Ð¸´·¢Âѳ²°©£¨PSOC£©ÖеÄDZÔÚ¼ÛÖµ£¬¶ø¸ÃÁìÓò³¤ÆÚÁÙ´²Ñо¿Êý¾ÝÈÔ½ÏΪȱ·¦¡£
´ËÇ°ÔÚ2025ÄêESMO´ó»áºÍ2025Äê¹ú¼Ê¸¾¿Æ°©Ö¢Ñ§»á£¨IGCS£©Äê»áÉϹ«²¼µÄÊý¾ÝÒÑÏÔʾ£¬mocertatug rezetecanÔÚ²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©£¨PROC£©ÖоßÓп¹Ö×Áö»îÐÔ[1-2]¡£Ò»ÏîÕë¶Ô²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©»¼ÕßµÄIIIÆÚÁÙ´²Ñо¿ÕýÔÚÖйú½øÐÐÖУ¨NCT06855069£©£¬¶øÓɸðÀ¼ËØÊ·¿Ë£¨GSK£©Ö÷µ¼µÄÒ»ÏîÈ«ÇòIIIÆÚÑо¿£¨NCT07286266£©Ò²½«ÓÚ2026Äê³õÆô¶¯¡£
Mocertatug rezetecan£¬Ò»ÖÖ°ÐÏòB7-H4µÄ¿¹ÌåµÏÍþ¹ú¼ÊÎïżÁªÎÓÃÓÚÖضȾÖεIJ¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕߣºÒ»Ï·Å±êÇ©IIÆÚÑо¿½á¹û
±¨¸æר³¡£º±Ú±¨Ñ²Õ¹
ÕªÒª±àºÅ£º#76/P06-01
±¨¸æʱ¼ä£º2026Äê2ÔÂ27ÈÕ 17:20¨C18:20£¨CET£©
±¨¸æ×÷ÕߣºÔ¬¹âÎÄ£¨¹ú¼Ò°©Ö¢ÖÐÐÄ/¹ú¼ÒÖ×ÁöÁÙ´²Ò½Ñ§Ñо¿ÖÐÐÄ/Öйúҽѧ¿ÆѧԺ±±¾©ÐºÍҽѧԺÖ×ÁöÒ½Ôº£©
Ñо¿½á¹û£º
Mocertatug rezetecanµ¥µÏÍþ¹ú¼ÊÖÎÁÆÔÚÖضȾÖεIJ¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕßÖÐÏÔʾ³öÁîÈ˹ÄÎèÇҳ־õĿ¹Ö×Áö»îÐÔ¡£ÖÐλËæ·Ã16.6£¨0.8-19.1£©¸öÔ£¬3Àý»¼Õß´ïµ½ÍêÈ«»º½â£¨CR£©£¬È·ÈϵĿ͹ۻº½âÂÊ (cORR)Ϊ64.5%¡£ÖÐλ»º½â³ÖÐøʱ¼ä £¨mDoR£©Îª13.8¸öÔ£¬ÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©Îª14.1¸öÔ¡£
Mocertatug rezetecanµ¥µÏÍþ¹ú¼ÊÖÎÁÆÔÚ²¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕßÖеݲȫÐÔ¿É¿Ø£¬Óë¼ÈÍùÁÙ´²¾ÑéÒ»Ö¡£×î³£¼ûµÄ¡Ý3¼¶ÖÎÁÆÆڼ䲻Á¼Ê¼þΪѪҺѧʵÑéÊÒ¼ì²éÒì³££¬Ö÷ҪΪÖÐÐÔÁ£Ï¸°û¼ÆÊý½µµÍ¡¢°×ϸ°û¼ÆÊý½µµÍºÍƶѪ¡£
Mocertatug rezetecan£¬Ò»ÖÖ°ÐÏòB7-H4µÄ¿¹ÌåµÏÍþ¹ú¼ÊÎïżÁªÎÁªºÏ±´·¥Öéµ¥¿¹ÓÃÓÚ²¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕߣºIÆÚÑо¿½á¹û
±¨¸æר³¡£º ÃÔÄã¿ÚÍ·±¨¸æר³¡3£ºÂѳ²°©
ÕªÒª±àºÅ£º #202/MO3-8
±¨¸æʱ¼ä£º2026Äê2ÔÂ27ÈÕ 14:55¨C15:55£¨CET£©
±¨¸æ×÷Õߣº Íõ³£Óñ£¨»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½Êôͬ¼ÃÒ½Ôº£©
Ñо¿½á¹û£º
Mocertatug rezetecanÁªºÏ±´·¥Öéµ¥¿¹ÔÚ²¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕßÖÐÏÔʾ³öÁîÈ˹ÄÎèµÄ¿¹Ö×Áö»îÐÔ¡£ÖÐλËæ·Ã3.9£¨2.8-8.3£©¸öÔ£¬26Àý»¼ÕߴﵽȷÈϵÄÍêÈ«»º½â»ò²¿·Ö»º½â£¬È·ÈϵĿ͹ۻº½âÂÊΪ72.2%¡£ÁíÓÐ2Àý»¼Õߴﵽδ¾È·ÈϵIJ¿·Ö»º½â£¬ÆäÓà8Àý»¼Õß´ïµ½¼²²¡Îȶ¨ÇÒÖ×ÁöËõС¡£
Mocertatug rezetecanÁªºÏ±´·¥Öéµ¥¿¹ÔÚ²¬Ãô¸Ð¸´·¢Âѳ²°©»¼ÕßÖеݲȫÐÔ¿É¿Ø£¬Óë¼ÈÍù±¨µÀµÄmocertatug rezetecanµ¥µÏÍþ¹ú¼Ê°²È«ÐÔÌØÕ÷ºÍ±´·¥Öéµ¥¿¹ÒÑÖª°²È«ÐÔÌØÕ÷Ò»Ö£¬Î´¹Û²ìµ½ÐµĻòµþ¼Ó¶¾ÐÔ¡£
¹ØÓÚMocertatug Rezetecan
Mocertatug rezetecan£¨HS-20089£©ÊǵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄµÄÒ»¿î°ÐÏòB7-H4µÄ¿¹ÌåµÏÍþ¹ú¼ÊÎïżÁªÎADC£©£¬ÓÃÓÚÖÎÁÆÂѳ²°©¼°ÆäËûʵÌåÁö¡£¸Ã²úÆ·ÔÚÖйúÕë¶Ô²¬Ä͵ÏÍþ¹ú¼ÊÂѳ²°©µÄÁÙ´²¿ª·¢ÒѽøÈëIIIÆڽ׶Σ¬Í¬Ê±Ò²ÔÚ¿ªÕ¹Õë¶Ô×Ó¹¬ÄÚĤ°©¼°ÆäËûʵÌåÁöµÄÑо¿¡£
2023Äê10Ô£¬µÏÍþÖƵÏÍþ¹ú¼ÊÊÚÓè¸ðÀ¼ËØÊ·¿Ë¹ØÓÚmocertatug rezetecanµÄÈ«Çò¶À¼ÒÐí¿É£¨²»°üÀ¨Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃźĮ́ÍåµØÇø£©£¬¸ðÀ¼ËØÊ·¿ËÕýÔÚͨ¹ýBEHOLDÏîÄ¿Íƽø¸Ã²úÆ·È«Çò¿ª·¢£¬°üÀ¨BEHOLD-1£¨NCT06431594£©I/IIÆÚÑо¿ºÍBEHOLD-2£¨NCT06796907£©Ñо¿¡£¸ðÀ¼ËØÊ·¿Ë½«ÓÚ2026ÄêÆô¶¯¸Ã²úÆ·¶àÏîÕë¶ÔÂѳ²°©ºÍ×Ó¹¬ÄÚĤ°©µÄIIIÆÚÊÔÑ飬°üÀ¨BEHOLD-OVARIAN01Ñо¿£¨NCT07286266£©ºÍBEHOLD-ENDOMETRIAL01Ñо¿£¨NCT07286331£©¡£
2025Äê5Ô£¬mocertatug rezetecan»ñÖйú¹ú¼ÒµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÄÉÈëÍ»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎÄⶨÊÊӦ֢ΪÓÃÓÚº¬²¬Ä͵ÏÍþ¹ú¼Ê¸´·¢ÉÏƤÐÔÂѳ²°©¡¢ÊäÂѹܰ©»òÔ·¢ÐÔ¸¹Ä¤°©»¼Õß¡£
¹ØÓÚPSOC
Âѳ²°©ÊÇ×î³£¼ûµÄ¸¾¿Æ¶ñÐÔÖ×ÁöÖ®Ò»¡£2022Ä꣬ȫÇòз¢Âѳ²°©²¡ÀýÔ¼324,603Àý£¬Î»ÁÐÅ®ÐÔ³£¼û¶ñÐÔÖ×ÁöµÚ°Ëλ£»Í¬ÄêËÀÍö²¡ÀýÔ¼206,956Àý£¬ÊÇÅ®ÐÔ°©Ö¢Ïà¹ØËÀÍöµÄµÚ°Ë´óÔÒò¡£2022Ä꣬ÖйúÂѳ²°©Ð·¢²¡ÀýΪ61,060Àý£¬ËÀÍö²¡ÀýΪ32,646Àý[3]¡£²¬Ãô¸ÐÂѳ²°©£¨PSOC£©Ö÷Òª²ÉÓÃÒÔ²¬ÀàΪ»ù´¡µÄ»¯ÁÆ£¬¿Éµ¥ÓûòÁªºÏ±´·¥Öéµ¥¿¹[4]£¬³õÆÚ»º½âÂʽϸߡ£È»¶ø£¬Ëæן´·¢´ÎÊýÔö¼Ó[5]¡¢ÀÛ»ý¶¾ÐÔ[6]ÒÔ¼°¼ÈÍùPARPÒÖÖƼÁ±©Â¶[7]£¬²¬ÀàµÏÍþ¹ú¼ÊÎïµÄÁÆЧÖð½¥Ï½µ£¬Í¹ÏÔÁ˶ԸüÓÐЧÇÒÄÍÊÜÐÔ¸ü¼ÑµÄÖÎÁÆ·½°¸µÄÆÈÇÐÐèÇó¡£
²Î¿¼ÎÄÏ×£º
1. ESMO 2025 | HANSOH PHARMA PRESENTS THE PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4-TARGETED ADC), IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC)-Press Releases-Hansoh Pharmaceutical Group Co., Ltd.
2. HANSOH PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025-Press Releases-Hansoh Pharmaceutical Group Co., Ltd.
3. International Agency for Research on Cancer. (2024). Cancer TODAY: GLOBOCAN 2022 (version 1.1). Retrieved April 26, 2025, from Global Cancer Observatory
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2025.
5. Kessous, R, et al. Int J Cancer. 2021; 148:2304-2312.
6. Tsao, L.R, et al. Clin Rev Allergy Immunol. 2022; 62:432-448.
7. P Harter, et al. Ann Oncol. 2025 Feb;36(2):185-196.
¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê
ÃâÔðÉùÃ÷
Ç°Õ°ÐÔ˵Ã÷
